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Summary  Previous  studies  have  reported  decreasing  hepatitis  C  virus  (HCV)
infection  rates  in  the  general  population.  However,  differential  susceptibility  in  insti-
tutionalized  populations  suggest  that  HCV  infection  is  even  more  prevalent  in  prison
populations  than  previously  reported  yet,  routine  screening  for  HCV  infection  among
prisoners  is  not  generally  available.  We  estimated  the  HCV  prevalence  and  identi-
ﬁed  associated  exposures  at  two  maximum-security  prisons  using  data  obtained  from
2788  inmates  from  the  Risk  Factors  for  Spread  of  Staphylococcus  aureus  in  Prisons
Study  in  New  York,  which  recruited  participants  from  January  2009  and  January
2013.  HCV  prevalence  was  10.1%  (n  =  295);  injection  drug  use,  injection  drug  use
sex  partners,  and  HIV  diagnosis  exhibited  the  strongest  associations  with  HCV  infec-
tion  in  multivariable  models,  adjusting  for  covariates.  Taken  together,  the  ﬁndings
of  the  present  study  provide  an  updated  estimate  of  HCV  prevalence  and  suggest
that  incarcerated  populations  represent  a  declining  yet  signiﬁcant  portion  of  the
hepatitis  epidemic.
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Ltd.  All  rights  reserved.∗ Corresponding author. Fax: +1 212 305 0722.
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Introduction
In comparison  with  the  general  population,  indi-
viduals in  correctional  systems  bear  a  dispropor-
tionately greater  burden  of  infectious  disease,
including hepatitis  C  virus  (HCV)  [1—4]. The
prevalence of  HCV  infection  among  incarcerated
populations  has  been  reported  to  range  from  9.6%
to 41%  compared  with  1%  to  2%  in  the  general
U.S. population  [2,4—9]. The  U.S.  established  a
national  reporting  system  for  conducting  surveil-
lance on  viral  hepatitis  to  direct  prevention  efforts
and to  control  and  evaluate  the  effect  of  these
activities [10].  Unfortunately,  this  system  is  highly
fragmented  and  poorly  developed,  with  particu-
lar regard  to  HCV,  providing  inaccurate  estimates
of the  current  burden  of  the  disease  [10,11].
Moreover, the  scope  of  the  hepatitis  epidemic  is
poorly understood  because  the  majority  of  pub-
lished  data  are  based  on  national  household  surveys
(e.g.,  NHANES),  which  exclude  institutionalized
populations,  including  those  who  are  incarcerated
[6].
HCV  is  a  viral  disease  that  results  in  inﬂam-
mation of  the  liver  and  is  linked  to  a  variety  of
adverse health  outcomes,  including  cirrhosis  and
hepatocellular  cancer  [10]. It  is  the  most  common
chronic bloodborne  infection  in  the  U.S.,  and  as
there is  no  effective  vaccine  or  post-exposure  pro-
phylaxis,  prevention  activities  to  reduce  the  risk
of infection  are  crucial  [12].  In  2013,  the  reported
median cost  of  treatment  varied  widely,  depend-
ing on  the  severity  of  HCV  infection  and  therapy
recommendation,  and  ranged  between  $83,509  and
$188,859 per  patient;  hospitalization  and  in-patient
costs increased  this  burden  twofold,  with  approx-
imately  24%  of  diagnosed  HCV  patients  requiring
hospital care  [13—15]. Thus,  understanding  the  risk
factors that  contribute  to  HCV  infection,  partic-
ularly  among  high-risk  populations,  may  improve
our understanding  of  the  progression  of  HCV-related
chronic conditions  and  facilitate  early  interventions
aimed at  reducing  these  health  risks  and  costs.
Previous studies  have  reported  decreasing
HCV infection  rates  in  the  general  population.
However, differential  susceptibility  in  institution-
alized populations  suggest  that  HCV  infection  is
even more  prevalent  in  prison  populations  than
previously  reported,  yet  routine  screening  for
HCV infection  among  prisoners  is not  generally
available [7,16,17].  Although  the  risk  factors  for
HCV infection  have  been  studied  extensively  in
the general  population  and  the  associations  are
well established,  studies  have  not  consistently
estimated  the  prevalence  or  identiﬁed  risk  factors
among  incarcerated  populations  [16].  The  purposes
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f  this  study  are:  (1)  to  estimate  the  prevalence
f HCV  infection  among  inmates  entering  and  in
wo New  York  State  prisons  and  (2)  to  identify
redictors of  HCV  infection  risk.
aterials and methods
ample and setting
ata  for  this  analysis  were  obtained  as  part
f a  5-year  NIH-funded  project  (Risk  Factors
or Spread  of  Staphylococcus  aureus  in  Pris-
ns, 5R01AI082536).  Detailed  information  on  the
tudy methodology  and  sampling  has  been  previ-
usly  described  [18,19]. Brieﬂy,  participants  were
ecruited  between  January  2009  and  January  2013
nd consisted  of  individuals,  aged  16  years  or
lder, who  were  incarcerated  at  two  maximum-
ecurity prison  facilities  in  New  York  State:  Sing
ing Correctional  Facility  for  men  and  Bedford
ills Correctional  Facility  for  women.  Participa-
ion was  voluntary,  and  compensation  was  not
rovided.  Written  informed  consent  was  obtained
rom all  participants.  This  study  was  approved
y the  institutional  review  boards  of  Columbia
niversity Medical  Center  and  the  New  York
tate Department  of  Corrections  and  Community
upervision.
ata collection
ive  trained  researchers  conducted  interviews  via
 structured  questionnaire  to  collect  demographic
nd behavioral  information.  In  addition,  inmate
edical  charts  were  reviewed  and  medical  data
ere abstracted.  Behavioral  information  included
he duration  and  frequency  of  the  following:  smok-
ng, injection  drug  use  (IDU),  tattooing,  and  body
iercing.  HCV  infection,  chronic  conditions,  and
exual behavior  information  as  well  as  the  diag-
ostic  tests  conducted  on  admission  were  obtained
rom the  medical  chart.  Because  HCV  infection  sta-
us was  abstracted  from  the  medical  chart  of  the
risoner,  the  diagnosis  was  not  conﬁrmed.  Prisoners
n the  study  facilities  were  only  screened  for  HCV
pon admission  if  they  presented  with  abnormal
iver function  tests  or  if  their  risk  proﬁle  suggested
igh-risk behavior.  Thus,  it is  likely  that  prisoners
ay misreport  HCV  status;  however,  those  with  HCV
nfection most  likely  have  the  disease.tatistical analysis
revalence  of  HCV  infection  as  well  as  inmate
emographic and  exposure  characteristics  were
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Table  1  Characteristics  of  participants  by  gender,  2009—2013.
Characteristic  N  (%)  Male  (N  =  1518)  (%)  Female  (N  =  1409)  (%)
Race
Non-Hispanic  white  621  (21.3)  154  (10.2)  487  (33.3)
Non-Hispanic  black  1453  (49.8)  844  (55.7)  609  (43.4)
Hispanic  673  (23.1)  444  (29.3)  229  (16.3)
Other  172  (5.9)  73  (4.8)  99  (7.1)
Age  (years),  mean  ±  SD 37.4  ±  10.9 37.8  ±  10.5 37.0  ±  11.4
Chronic  conditions
HCV  295  (10.1) 112  (7.4) 183  (13.0)
HBV  38  (1.3)  26  (1.7)  12  (0.9)
HIV  119  (4.1)  34  (2.2)  85  (6.0)
Diabetes  197  (6.7)  62  (4.1)  135  (9.6)
Current  smoker,  tobacco  1896  (64.8)  931  (61.3)  965  (68.5)
Injection  drug  use,  ever  258  (8.9)  79  (5.2)  179  (12.9)
Sexual  activity
Multiple  partners  536  (18.3)  217  (27.6)  43  (6.9)
Sex  with  injection  drug  users  84  (2.9)  18  (2.3)  21  (3.4)
Sex  with  prostitutes  284  (9.7)  88  (5.8)  196  (13.9)
Sexually  transmitted  diseasesa 536  (18.3)  114  (7.5)  422  (30.0)
Tattoos 1740  (59.5)  922  (60.7)  818  (58.1)
Piercings 1560  (53.3)  621  (40.9)  939  (66.6)
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a Includes syphilis, gonorrhea, HPV, chlamydia, and herpes.
stimated  via  sample  proportions.  Bivariate
nalyses were  performed  to  assess  differences  in
nmate characteristics  by  HCV  status  using  2 tests,
isher’s exact  tests  or  Student’s  t  tests,  as  appro-
riate.  After  adjusting  for  age,  the  relationship
etween HCV  infection  and  inmate  characteristics
as assessed.  A  multivariable  logistic  regression
odel was  developed  to  determine  associations
etween HCV  infection  and  reported  demographic
haracteristics,  known  risk  factors,  and  other
xposures. Interactions  by  gender  or  age  were
xamined. Statistical  analyses  were  performed
sing SAS  version  9.3  (SAS  Institute,  Inc.,  Cary,
orth  Carolina).
esults
n  this  analysis,  2788  inmates  were  included  (1518
ales;  1409  females).  A  total  of  295  HCV  infec-
ions were  documented  in  this  study  population,
ith an  overall  prevalence  of  10.1%.  Participant
haracteristics  are  reported  in  Table  1. The  mean
ge was  37.4  ±  10.9  years.  The  largest  proportion
f participants  (49.8%)  was  non-Hispanic  black;
3.1% were  Hispanic.  Inmates,  1.3%  and  4.1%,
ad a  diagnosis  of  hepatitis  B  virus  (HBV)  and
uman immunodeﬁciency  virus  (HIV),  respectively;
.7% had  diabetes.  Potential  behavioral  risk  fac-
ors included  STIs  (18.3%),  history  of  IDU  (8.9%),
ex with  multiple  partners  (18.3%),  sex  partners
D
I
tdeﬁciency virus.
ho  were  IDUs  (2.9%),  sex  with  prostitutes  (9.7%),
attoos  (59.5%),  and  piercings  (53.3%).  The  results
rom the  interaction  analysis  indicated  that  HCV
revalence  and  its  associated  risks  did  not  vary  by
ender (results  not  shown).
The results  from  the  multivariable  models,
djusted for  age,  assessing  HCV  infection  and
emographic and  behavioral  risk  factors  are
eported in  Table  2. The  prevalence  of  HCV  infec-
ion was  signiﬁcantly  elevated  among  inmates  who
eported any  IDU  (adjusted  prevalence  OR  =  64.8;
5% CI  =  37.4,  112.1),  sex  partners  who  were
DUs (adjusted  prevalence  OR  =  8.0,  95%  CI  =  3.9,
6.2), and  a diagnosis  of  HIV  (adjusted  prevalence
R =  4.3;  95%  CI  = 2.2,  8.3).  In  addition,  the  odds  of
CV infection  was  increased  twofold  among  non-
ispanic  black  inmates  compared  with  non-Hispanic
hite inmates  (adjusted  prevalence  OR  =  2.3;  95%
I = 1.4,  3.6)  and  was  increased  threefold  among
hose who  reported  any  tattoos  and  STIs  (adjusted
revalence OR  =  2.9;  95%  CI  =  1.9,  4.5  & OR  =  3.2;
5% CI  =  2.1,  4.9,  respectively).  Risk  behaviors  not
tatistically  associated  with  HCV  infection  included
 history  of  HBV  infection,  sexual  activity  with  mul-
iple partners,  and  piercings.iscussion
n  the  present  cross-sectional  study,  we  estimated
he prevalence  of  HCV  infection  and  identiﬁed
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Table  2  Prevalence  of  HCV  by  race,  chronic  conditions,  smoking  status,  injection  drug  use,  sexual  activity,  tattoos,
and  piercings,  2009—2013.
Characteristic  %  with  HCV  Multivariable  logistic  prevalence  OR  (95%  CI)
Race/Ethnicity
Non-Hispanic  white  97  (33.1)  1.0
Non-Hispanic  black  90  (30.7)  2.3  (1.4,  3.6)
Hispanic  87  (29.7)  1.0  (0.6,  1.7)
Other  19  (6.5) 1.6  (0.7,  3.8)
Chronic  conditions
HBV  18  (6.1) 3.4  (1.0,  12.2)
HIV  47  (15.9)  4.3  (2.2,  8.3)
Diabetes  36  (12.2)  1.6  (0.9,  2.9)
Current  smoker,  tobacco  225  (76.3)  2.3  (1.5,  3.6)
Injection  drug  use,  ever  168  (57.4)  64.8  (37.4,  112.1)
Sexual  activity
Multiple  partners  47  (15.9)  1.7  (0.9,  3.0)
Sex  with  injection  drug  users  40  (13.6)  8.0  (3.9,  16.2)
Sex  with  prostitutes  73  (24.8)  2.4  (1.4,  3.9)
Sexually  transmitted  infectionsa 91  (30.9)  3.2  (2.1,  4.9)
Tattoos  196  (66.4)  2.9  (1.9,  4.5)
Piercings 156  (52.9)  1.2  (0.8,  1.8)
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HCI = conﬁdence interval; HCV = hepatitis C virus; HBV = hepatiti
a Includes syphilis, gonorrhea, human papillomavirus, chlam
risk  factors  associated  with  HCV  positivity  at  two
maximum-security  prisons.  The  prevalence  rate  in
this population  was  10.1%.  Inmates  with  HCV  infec-
tion were  signiﬁcantly  more  likely  to  report  a
history  of  IDU,  sexual  activity  with  IDUs,  and  HIV
diagnosis.  The  ﬁndings  of  the  present  study  provide
an updated  estimate  of  HCV  prevalence  and  suggest
that incarcerated  populations  represent  a  declining
yet signiﬁcant  portion  of  the  hepatitis  epidemic.
The high  seroprevalence  of  HCV  among  inmates
is a  serious  public  health  concern  for  several  rea-
sons. First,  infected  individuals  may  continue  to
engage in  high-risk  behaviors  and  infect  others
while  incarcerated  [16].  The  results  of  our  study
identiﬁed additional  inmate  exposures  that  may
facilitate  HCV  infection,  including  tattoos.  Tat-
tooing instruments  could  potentially  serve  as  a
transmission  vehicle,  particularly  given  the  large
number  of  inmates  with  chronic  infections  [4,16].
For example,  in  one  study,  prisoners  reported  know-
ingly receiving  a  tattoo  with  a  previously  used
instrument and/or  ink  [20]. Despite  correctional
system prohibitions  against  tattoos,  transmission
of HCV  infection  may  still  occur  as  a  result  of
shared instruments.  Second,  because  inmates  with
HCV infection  may  not  be  aware  of  their  infec-
tion status  and  because  systematic  screening  is
often not  offered  in  this  setting  [7,17],  interven-
tions designed  to  prevent  transmission  from  close
contact  cannot  be  implemented  effectively,  and
subsequent  health  care  services  for  HCV-infected
individuals could  prove  costly.  Third,  inmates  are
t
t
s
trus; HIV = human immunodeﬁciency virus; OR = odds ratio.
, and herpes.
ften  released  to  the  community  or  transferred
o another  correctional  facility;  thus,  infected
nmates could  serve  as  a reservoir  for  ongoing  HCV
ransmission  [21].
There  are  several  important  limitations  to  our
tudy.  First,  HCV  status  was  obtained  from  medi-
al records.  As  a  result,  we  do  not  know  how  the
iagnosis  was  conﬁrmed  because  the  prisoners  in
hese facilities  were  screened  for  HCV  upon  admis-
ion only  if  they  had  abnormal  liver  function  tests
r if  their  risk  proﬁle  upon  admission  indicated  high
isk (in  the  absence  of an  HCV  screen,  the  inmate
ight self-report  being  seropositive  and  this  would
e listed  as  such  in  the  medical  record).  Thus,  in
his population,  it  is  likely  that  some  inmates  mis-
eport their  HCV  status;  as  a  result,  the  prevalence
f HCV  is likely  underestimated.  However,  those
iagnosed with  HCV  most  likely  have  the  disease.
elf-reporting a HCV  infection,  a highly  stigma-
ized condition,  has  been  found  to  be  reliable  in
umerous  epidemiological  and  intervention  studies
22—24]. For  example,  in  a large  multi-site  study  of
oung IDUs  in  metropolitan  areas  throughout  the
S, the  predictive  validity  of  HCV  positivity  was
stimated  at  94%  [22]. Thus,  given  these  data  to
upport  the  predictive  validity  of  HCV  positivity  and
he paucity  of  information  on  the  risk  factors  for
CV transmission  within  US  correctional  systems,
aking  advantage  of  the  opportunity  provided  in
his study  setting  to  link  epidemiological  data  to
elf-reported  infection  is  warranted.  It  is  also  likely
hat exposure  to  high  risk  factors  (during  the  risk
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roﬁle  screening)  was  also  misreported;  neverthe-
ess, we  do  not  suspect  that  inmates  reported  these
xposures  differentially.
Sustained  control  and  prevention  of  HCV  trans-
ission within  correctional  systems  is  urgent,  and
dentiﬁcation  of  potential  factors  associated  with
CV risk  in  this  setting  provides  an  important  pub-
ic health  opportunity.  Screening,  diagnosis,  and
revention  services  must  be  incorporated  into  cor-
ectional  health  systems  to  reduce  the  progression
f clinical  disease  and  to  stem  the  transmission  of
CV infection.
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